Think

AMAG Pharmaceuticals (NASDAQ:AMAG) saw a sharp drop in its debt in the past week following the release of its actual results in sales. Although the pharma company saw its sales rise to a new record in this past year, investors are concerned as its top-selling drug, Makena, is set to lose its patent exclusivity in 2018. The maternal drug aid currently makes up 70% of AMAG's sales and with no defense to differentiate it from generics, investors are uncertain of how the company will be able to cope.

Banca Monte dei Paschi di Siena (IT: BMPS) has been in the headlines the past few months over concerns that it wouldn't be able to cover its bad outstanding debts. In November, the bank announced that it was seeking a 5 billion euro capital injection in order to cover these debts in December, but the plan is currently at risk following the recent government referendum decision. Investors have been skeptical about the banks recapitalization, but reports on Tuesday have suggested that the Italian government will participate in the capital relief. It is crucial that BMPS receive aid quickly to avoid a collapse of the bank and possible contagion to others.

The world's oldest lender experienced a scare with bad loans earlier this January, but was able to avoid disaster through an accounting restatement and help from the government to repackage non-performing loans into bonds.

Advantage Data Inc. provides best-in-house Credit Default Swap (CDS) data that allows users to make graphical and analytical comparison of Bonds, Loans and CDS in a single platform. Refer to ADI’s sample white paper on CDS and request a free demo to learn more about ADI’s proprietary tools.